Holen Sie sich die Stockscreener-App
26.47
2.47%
-0.66
Handel nachbörslich:
26.50
0.03
+0.11%
Schlusskurs vom Vortag:
$27.13
Offen:
$26.81
24-Stunden-Volumen:
961.35K
Relative Volume:
0.80
Marktkapitalisierung:
$1.76B
Einnahmen:
$5.79M
Nettoeinkommen (Verlust:
$-199.61M
KGV:
-8.794
EPS:
-3.01
Netto-Cashflow:
$-188.48M
1W Leistung:
+0.92%
1M Leistung:
+8.22%
6M Leistung:
+48.74%
1J Leistung:
-12.62%
1-Tages-Spanne:
$26.45
$27.44
1-Wochen-Bereich:
$24.50
$27.98
52-Wochen-Spanne:
$14.40
$30.48
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Vergleichen Sie CLDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
26.47 | 1.78B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Published on: 2025-10-14 10:43:50 - newser.com
Is it too late to sell Celldex Therapeutics Inc.Portfolio Performance Report & Pattern Based Trade Signal System - newser.com
Why analysts remain bullish on Celldex Therapeutics Inc. stockQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
Best data tools to analyze Celldex Therapeutics Inc. stockLong Setup & Expert Approved Momentum Trade Ideas - newser.com
Barclays Initiates Coverage of Celldex Therapeutics (CLDX) with Underweight Recommendation - Nasdaq
How Investors Are Reacting To Celldex Therapeutics (CLDX) After Barclays Shines Spotlight on Biotech Innovation - Sahm
Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade) (NASDAQ:CLDX) - Seeking Alpha
Chart overlay techniques for tracking Celldex Therapeutics Inc.Market Growth Report & Fast Momentum Stock Entry Tips - newser.com
Real time alert setup for Celldex Therapeutics Inc. performanceQuarterly Portfolio Review & Advanced Swing Trade Entry Plans - newser.com
Barclays initiates Celldex Therapeutics stock with Underweight rating By Investing.com - Investing.com Canada
Published on: 2025-10-13 08:38:10 - newser.com
Barclays Initiates Celldex Therapeutics at Underweight With $25 Price Target - MarketScreener
Published on: 2025-10-13 01:55:53 - newser.com
Is Celldex Therapeutics Inc. stock a bargain at current levelsJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Is Celldex Therapeutics Inc. reversing from oversold territoryPortfolio Gains Report & Daily Technical Stock Forecast Reports - newser.com
Chronic Spontaneous Urticaria Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight - Barchart.com
How interest rate cuts could boost Celldex Therapeutics Inc. stockPortfolio Value Report & Daily Stock Momentum Reports - newser.com
Celldex Therapeutics (NASDAQ:CLDX) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Urticaria Pipeline Drugs Insights Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight - Barchart.com
Celldex Bets Big On Its Allergy Pipeline Breakthroughs - Finimize
Analyzing Celldex Therapeutics Inc. with risk reward ratio charts2025 Market Outlook & Weekly High Conviction Ideas - newser.com
Is Celldex Therapeutics Inc. still worth holding after the dip2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
When is the best time to exit Celldex Therapeutics Inc.2025 Fundamental Recap & Weekly High Momentum Picks - newser.com
Will Celldex Therapeutics Inc. rebound enough to break evenMarket Risk Report & Reliable Intraday Trade Alerts - newser.com
Celldex Therapeutics Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations - Markets Mojo
Celldex Therapeutics (NASDAQ:CLDX) Share Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
How moving averages guide Celldex Therapeutics Inc. trading2025 Institutional Moves & Consistent Growth Stock Picks - newser.com
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving Average – Here’s What Happened - Defense World
Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cu... - ADVFN
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
One Celldex Therapeutics Insider Raised Stake By 40% In Previous Year - 富途牛牛
Sovran Advisors LLC Purchases New Shares in Celldex Therapeutics, Inc. $CLDX - MarketBeat
The Bull Case For Celldex Therapeutics (CLDX) Could Change Following Barzolvolimab's Broad Efficacy Shown in CSU Data - Sahm
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Celldex Therapeutics Inc-Aktie (CLDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Marucci Anthony S | PRESIDENT & CEO |
Nov 11 '24 |
Buy |
26.82 |
11,500 |
308,430 |
40,284 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):